In this webinar, three speakers will present the application of microfluidic, nanoliter-scale Gyrolab® immunoassay platform for ligand-binding assays.
This webinar was presented as part of Oxford Global Biomarkers Week on March 18, 2021.
Gyrolab Bioaffy 4000 CD: Extending Immunoassay Sensitivity in a Microfluidic Platform
John Chappell, Application & Service Director EMEA and Asia Pacific, Gyros Protein Technologies
Improving Existing Multidomain Biotherapeutic (MDB) PK Assay with Gyrolab 4000 CD
Carina Carter, Senior Scientist, EMD Serono
Development of a sensitive assay for detection of a serum biomarker using Gyrolab Bioaffy 4000 CDs.
Claire Seal, Principal Scientist, F-Star Therapeutics
If you have problems to view the webinar please contact email@example.com